SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    B Vrijens, J Urquhart, Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials, Clinical Pharmacology & Therapeutics, 2014, 95, 6, 617

    CrossRef

  2. 2
    Mahesh K B Parmar, James Carpenter, Matthew R Sydes, More multiarm randomised trials of superiority are needed, The Lancet, 2014, 384, 9940, 283

    CrossRef

  3. 3
    Maryann Mazer-Amirshahi, Gerald Sokol, John Anker, Louis Cantilena, A review of pharmaceutical labeling for overdose treatment and toxicity data, Pharmacoepidemiology and Drug Safety, 2013, 22, 3
  4. 4
    Christian G. Daughton, Ilene Sue Ruhoy, Lower-dose prescribing: Minimizing “side effects” of pharmaceuticals on society and the environment, Science of The Total Environment, 2013, 443, 324

    CrossRef

  5. 5
    G Pillai, G Davies, P Denti, J-L Steimer, H McIlleron, S Zvada, E Chigutsa, E Ngaimisi, F Mirza, B Tadmor, N H G Holford, Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa, CPT: Pharmacometrics & Systems Pharmacology, 2013, 2, 8, e69

    CrossRef

  6. 6
    Principles of Toxicology Testing, Second Edition, 2013,

    CrossRef

  7. 7
    Terrence F. Blaschke, Lars Osterberg, Bernard Vrijens, John Urquhart, Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories, Annual Review of Pharmacology and Toxicology, 2012, 52, 1, 275

    CrossRef

  8. 8
    Lorenzo A. DiCarlo, Role for direct electronic verification of pharmaceutical ingestion in pharmaceutical development, Contemporary Clinical Trials, 2012, 33, 4, 593

    CrossRef

  9. 9
    Laurent Bourguignon, Michel Ducher, David Matanza, Nathalie Bleyzac, Mathieu Uhart, Emmanuel Odouard, Pascal Maire, Sylvain Goutelle, The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study, Fundamental & Clinical Pharmacology, 2012, 26, 2
  10. 10
    K Nakashima, M Narukawa, M Takeuchi, Approaches to Japanese Dose Evaluation in Global Drug Development: Factors That Generate Different Dosages Between Japan and the United States, Clinical Pharmacology & Therapeutics, 2011, 90, 6, 836

    CrossRef

  11. 11
    Hans-Georg Eichler, Eric Abadie, Alasdair Breckenridge, Bruno Flamion, Lars L. Gustafsson, Hubert Leufkens, Malcolm Rowland, Christian K. Schneider, Brigitte Bloechl-Daum, Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response, Nature Reviews Drug Discovery, 2011, 10, 7, 495

    CrossRef

  12. 12
    Kae Nakashima, Mamoru Narukawa, Yoshiko Kanazu, Masahiro Takeuchi, Differences Between Japan and the United States in Dosages of Drugs Recently Approved in Japan, The Journal of Clinical Pharmacology, 2011, 51, 4
  13. 13
    Kenneth I. Maynard, Hormesis Pervasiveness and its Potential Implications for Pharmaceutical Research and Development, Dose-Response, 2011, 9, 3, 377

    CrossRef

  14. 14
    Adam F. Cohen, Developing drug prototypes: pharmacology replaces safety and tolerability?, Nature Reviews Drug Discovery, 2010, 9, 11, 856

    CrossRef

  15. 15
    Clinical Toxicology, 2010,

    CrossRef

  16. 16
    R Lledó-García, S Hennig, MO Karlsson, Comparison of Dose-Finding Designs for Narrow-Therapeutic-Index Drugs: Concentration-Controlled vs. Dose-Controlled Trials, Clinical Pharmacology & Therapeutics, 2009, 86, 1, 62

    CrossRef

  17. 17
    Masahiko Nishiyama, Hidetaka Eguchi, Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy, Advanced Drug Delivery Reviews, 2009, 61, 5, 402

    CrossRef

  18. 18
    Joel Lexchin, Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary, Health Policy, 2009, 91, 2, 142

    CrossRef

  19. 19
    Adam Cohen, Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development, Clinical Pharmacokinetics, 2008, 47, 6, 373

    CrossRef

  20. 20
    Y Hong, J Dingemanse, DE Mager, Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren, Clinical Pharmacology & Therapeutics, 2008, 84, 1, 136

    CrossRef

  21. 21
    Henry J. Malinowski, Agnes Westelinck, Junko Sato, Ting Ong, Same Drug, Different Dosing: Differences in Dosing for Drugs Approved in the United States, Europe, and Japan, The Journal of Clinical Pharmacology, 2008, 48, 8
  22. 22
    Mary K. Olson, The risk we bear: The effects of review speed and industry user fees on new drug safety, Journal of Health Economics, 2008, 27, 2, 175

    CrossRef

  23. 23
    Shiew-Mei Huang, Myong-Jin Kim, Federico Goodsaid, Felix Frueh, Lawrence Lesko, Genomics, 2008,

    CrossRef

  24. 24
    C C Peck, J T Cross, “Getting the Dose Right”: Facts, a Blueprint, and Encouragements, Clinical Pharmacology & Therapeutics, 2007, 82, 1, 12

    CrossRef

  25. 25
    Paul Rolan, Meindert Danhof, Donald Stanski, Carl Peck, Current issues relating to drug safety especially with regard to the use of biomarkers: A meeting report and progress update, European Journal of Pharmaceutical Sciences, 2007, 30, 2, 107

    CrossRef

  26. 26
    Stephen P. Glasser, Maribel Salas, Elizabeth Delzell, Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems, The Journal of Clinical Pharmacology, 2007, 47, 9
  27. 27
    Katarina Ilic, Nenad Ugresic, Pharmacovigilance in clinical trials, Vojnosanitetski pregled, 2007, 64, 4, 265

    CrossRef

  28. 28
    Sarika Saggar, Howard I. Maibach, Polymorphic Cytochrome P450 Enzymes and Post-Marketing Drug Dosage Revisions: Clinical Relevance to Dermatologic Therapies, Cutaneous and Ocular Toxicology, 2007, 26, 3, 171

    CrossRef

  29. 29
    Andrew Hill, Kiat Ruxrungtham, Mattana Hanvanich, Christine Katlama, Eva Wolf, Vincent Soriano, Ana Milinkovic, Jose Gatell, Esteban Ribera, Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment, Expert Opinion on Pharmacotherapy, 2007, 8, 5, 679

    CrossRef

  30. 30
    Principles of Toxicology Testing, 2007,

    CrossRef

  31. 31
    Shiew-Mei Huang, Federico Goodsaid, Atiqur Rahman, Felix Frueh, Lawrence J. Lesko, Application of Pharmacogenomics in Clinical Pharmacology, Toxicology Mechanisms and Methods, 2006, 16, 2-3, 89

    CrossRef

  32. 32
    Rashmi R Shah, Can pharmacogenetics help rescue drugs withdrawn from the market?, Pharmacogenomics, 2006, 7, 6, 889

    CrossRef

  33. 33
    Mieko Tamaoki, Hiroshi Gushima, Kiichiro Tsutani, 1st DIA Annual Japan Workshop for Pharmacogenomics in Tokyo, Pharmacogenomics, 2005, 6, 2, 103

    CrossRef

  34. 34
    P. Stolk, E. R. Heerdink, H. G. M. Leufkens, Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems, European Journal of Clinical Pharmacology, 2005, 61, 3, 243

    CrossRef

  35. 35
    Siv Jönsson, Mats O. Karlsson, Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug, European Journal of Pharmaceutical Sciences, 2005, 25, 1, 123

    CrossRef

  36. 36
    Donald R. Stanski, Malcolm Rowland, Lewis B. Sheiner, Getting the Dose Right: Report From the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) Conference on Optimizing Drug Development, Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 2, 199

    CrossRef

  37. 37
    Rashmi R Shah, Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules, Expert Opinion on Drug Safety, 2005, 4, 1, 103

    CrossRef

  38. 38
    R. R. Shah, Pharmacogenetics in drug regulation: promise, potential and pitfalls, Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1460, 1617

    CrossRef

  39. 39
    Mary K. Olson, Are novel drugs more risky for patients than less novel drugs?, Journal of Health Economics, 2004, 23, 6, 1135

    CrossRef

  40. 40
    J. Robert Powell, Clinical Pharmacists Save Thousands of Lives: Big Decrease in Dose-Related Adverse Effects, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004, 24, 3
  41. 41
    Kwame N Atuah, Dyfrig Hughes, Munir Pirmohamed, Clinical Pharmacology, Drug Safety, 2004, 27, 8, 535

    CrossRef

  42. 42
    Rashmi R. Shah, Drug development and use in the elderly: search for the right dose and dosing regimen, British Journal of Clinical Pharmacology, 2004, 58, 5
  43. 43
    Leslie A. Kenna, Lewis B. Sheiner, Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods, Statistics in Medicine, 2004, 23, 23
  44. 44
    Rashmi R Shah, Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes, Drug Safety, 2004, 27, 3, 145

    CrossRef

  45. 45
    Lawrence Lesko, Chandrahas Sahajwalla, New Drug Development, 2004,

    CrossRef

  46. 46
    Current Awareness: Pharmacoepidemiology and Drug Safety, Pharmacoepidemiology and Drug Safety, 2003, 12, 2
  47. 47
    Robert J. Temple, Defining dose decrease, Pharmacoepidemiology and Drug Safety, 2003, 12, 2
  48. 48
    Carl C. Peck, Postmarketing drug dosage changes, Pharmacoepidemiology and Drug Safety, 2003, 12, 5
  49. 49
    H. A. J. Struijker Boudier, A drug is not a drug is not a drug: a commentary, Pharmacoepidemiology and Drug Safety, 2002, 11, 6
  50. 50
    John Talbot, Marianne Keisu, Lars Ståhle, Clinical Trials—Collecting Safety Data and Establishing the Adverse Drug Reactions Profile,
  51. 51
    John Urquhart, Bernard Vrijens, Introduction to Pharmionics: The Vagaries in Ambulatory Patients' Adherence to Prescribed Drug Dosing Regimens, and Some of Their Clinical and Economic Consequences,
  52. 52
    John Urquhart, Bernard Vrijens, Patient Adherence to Prescribed Drug Dosing Regimens in Ambulatory Pharmacotherapy,
  53. 53
    Alette M. Wessels, Robert R. Bies, John Urquhart, Personalized Medicine (Predictive and Preventive), Encyclopedia of Molecular Cell Biology and Molecular Medicine,
  54. 54
    Thierry Buclin, Pharmacology, Pharmaceutical Sciences Encyclopedia,
  55. 55
    Chevret Sylvie, Therapeutic Dose Range, Wiley Encyclopedia of Clinical Trials,
  56. 56
    Chevret Sylvie, Therapeutic Dose Range, Wiley StatsRef: Statistics Reference Online,
  57. 57
    Brian L. Strom, What is Pharmacoepidemiology?,